A detailed history of Barclays PLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Barclays PLC holds 424,277 shares of FATE stock, worth $704,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
424,277
Previous 424,277 -0.0%
Holding current value
$704,299
Previous $1.49 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$3.12 - $5.57 $940,333 - $1.68 Million
301,389 Added 245.26%
424,277 $1.49 Million
Q2 2024

Aug 14, 2024

SELL
$3.26 - $7.08 $656,417 - $1.43 Million
-201,355 Reduced 62.1%
122,888 $403,000
Q1 2024

May 15, 2024

SELL
$3.54 - $8.35 $124,367 - $293,352
-35,132 Reduced 9.78%
324,243 $2.38 Million
Q4 2023

Feb 15, 2024

BUY
$1.65 - $3.94 $397,029 - $948,058
240,624 Added 202.63%
359,375 $1.34 Million
Q3 2023

Nov 07, 2023

SELL
$2.02 - $5.04 $727,902 - $1.82 Million
-360,348 Reduced 75.21%
118,751 $252,000
Q2 2023

Aug 03, 2023

SELL
$4.76 - $6.59 $103,401 - $143,154
-21,723 Reduced 4.34%
479,099 $2.28 Million
Q1 2023

May 04, 2023

BUY
$4.24 - $11.12 $1 Million - $2.63 Million
236,947 Added 89.8%
500,822 $2.86 Million
Q4 2022

Feb 13, 2023

BUY
$9.86 - $23.83 $837,705 - $2.02 Million
84,960 Added 47.49%
263,875 $2.66 Million
Q3 2022

Nov 03, 2022

BUY
$21.04 - $36.06 $3.33 Million - $5.7 Million
158,098 Added 759.47%
178,915 $4.01 Million
Q2 2022

Aug 12, 2022

SELL
$17.78 - $42.39 $10,330 - $24,628
-581 Reduced 2.72%
20,817 $516,000
Q1 2022

May 16, 2022

SELL
$29.67 - $60.28 $2.52 Million - $5.11 Million
-84,820 Reduced 79.85%
21,398 $830,000
Q4 2021

Feb 14, 2022

BUY
$47.84 - $64.34 $2.46 Million - $3.31 Million
51,470 Added 94.01%
106,218 $6.22 Million
Q3 2021

Nov 09, 2021

BUY
$59.27 - $95.73 $723,331 - $1.17 Million
12,204 Added 28.69%
54,748 $3.24 Million
Q2 2021

Aug 13, 2021

SELL
$67.25 - $92.52 $4.52 Million - $6.22 Million
-67,235 Reduced 61.25%
42,544 $3.69 Million
Q1 2021

May 13, 2021

SELL
$72.16 - $117.4 $1.45 Million - $2.36 Million
-20,070 Reduced 15.46%
109,779 $9.05 Million
Q4 2020

Feb 11, 2021

SELL
$38.09 - $100.95 $1.11 Million - $2.94 Million
-29,142 Reduced 18.33%
129,849 $11.8 Million
Q3 2020

Nov 12, 2020

BUY
$30.41 - $40.5 $679,268 - $904,648
22,337 Added 16.35%
158,991 $6.36 Million
Q2 2020

Aug 12, 2020

BUY
$20.21 - $35.23 $547,327 - $954,098
27,082 Added 24.72%
136,654 $4.69 Million
Q1 2020

May 13, 2020

BUY
$17.28 - $31.88 $845,320 - $1.56 Million
48,919 Added 80.65%
109,572 $2.43 Million
Q4 2019

Feb 10, 2020

BUY
$13.39 - $20.73 $73,216 - $113,351
5,468 Added 9.91%
60,653 $1.19 Million
Q3 2019

Nov 14, 2019

SELL
$15.47 - $22.5 $329,928 - $479,857
-21,327 Reduced 27.87%
55,185 $858,000
Q2 2019

Aug 14, 2019

BUY
$15.61 - $20.44 $682,250 - $893,350
43,706 Added 133.23%
76,512 $1.55 Million
Q1 2019

May 15, 2019

BUY
$13.15 - $18.71 $4,563 - $6,492
347 Added 1.07%
32,806 $576,000
Q4 2018

Feb 14, 2019

SELL
$11.48 - $16.98 $12,260 - $18,134
-1,068 Reduced 3.19%
32,459 $416,000
Q3 2018

Nov 14, 2018

BUY
$8.75 - $16.29 $228,243 - $424,924
26,085 Added 350.51%
33,527 $547,000
Q2 2018

Aug 14, 2018

SELL
$9.16 - $13.48 $104,085 - $153,173
-11,363 Reduced 60.43%
7,442 $85,000
Q1 2018

May 15, 2018

BUY
$6.3 - $13.77 $79,235 - $173,185
12,577 Added 201.94%
18,805 $184,000
Q4 2017

Feb 14, 2018

BUY
$3.94 - $6.64 $13,967 - $23,538
3,545 Added 132.13%
6,228 $38,000
Q3 2017

Nov 14, 2017

BUY
$2.6 - $4.31 $6,975 - $11,563
2,683
2,683 $11,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.